Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus and Perifosine for Recurrent Malignant Gliomas
NCT01051557Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2010
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus and perifosine in malignant glioma and glioblastoma (GBM), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose of Temsirolimus at 28 days, 6 Month Progression-free Survival and 1 more. Started Jan 2010; status: completed.
02
Drugs
temsirolimusperifosine
03
Conditions
malignant gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT01051557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01051557.